Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

NCT00083720 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms
Metastases
Neoplasm

Interventions

BIOLOGICAL: cetuximab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]